Orbimed Advisors LLC Passage Bio, Inc. Transaction History
Orbimed Advisors LLC
- $3.21 Billion
- Q1 2025
A detailed history of Orbimed Advisors LLC transactions in Passage Bio, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 7,034,626 shares of PASG stock, worth $40.6 Million. This represents 0.08% of its overall portfolio holdings.
Number of Shares
7,034,626
Previous 7,404,869
5.0%
Holding current value
$40.6 Million
Previous $4.22 Million
41.66%
% of portfolio
0.08%
Previous 0.11%
Shares
7 transactions
Others Institutions Holding PASG
# of Institutions
44Shares Held
36.4MCall Options Held
50.3KPut Options Held
0-
Lynx1 Capital Management LP San Juan, PR9.26MShares$53.4 Million1.2% of portfolio
-
Vestal Point Capital, LP New York, NY6.1MShares$35.2 Million0.15% of portfolio
-
New Leaf Venture Partners, L.L.C. New York, NY2.5MShares$14.4 Million1.97% of portfolio
-
Erste Asset Management Gmb H Vienna, C42.46MShares$14.2 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.07MShares$12 Million0.0% of portfolio
About Passage BIO, Inc.
- Ticker PASG
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 54,463,200
- Market Cap $314M
- Description
- Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 ...